Table 6.

In a randomized trial follow-up study, predictors of seroconversion and antibody avidity in Kenyan infants receiving 5 mg iron daily or no-iron control for 4 months, and given measles vaccine at age 9 mo, measured end of intervention (age 11.5 mo).

	Odds ratio	95% CI
Seronegative at end of intervention: R2 = 0.211
Control group	3.1	0.985, 9.729 (p = 0.0531)
Iron deficiency anemia	2.9	0.918, 9.358
Weight-for-height z-score	0.6	0.416, 0.963
Age	0.4	0.203, 0.921
Retinol binding protein	0.2	0.030, 1.334
Low avidity at end of intervention: R2 = 0.264
Control group	3.2	1.040, 9.647 (p = 0.0425)
Iron deficiency anemia	1.1	0.383, 2.925
Weight-for-height z-score	0.7	0.518, 1.081
Age	0.3	0.183, 0.600 (p = 0.0003)
Retinol binding protein	1.5	0.251, 8.732

Analyzed using logistic regression analyses.